Skip to content

Clinical trials

Completed Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive Phase: Not applicable Status: Completed Clear all

36 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20012
20031
20041
20051
20061
20073
20082
20093
20101
20111
20121
20132
20153
20171
20192
20203
20211
20221

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed36

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center2
National Heart, Lung, and Blood Institute (NHLBI)2
Scripps Health2
University Hospital, Bordeaux2
University of Illinois at Chicago2
Advice Pharma Group srl1
American University of Beirut Medical Center1
Ann & Robert H Lurie Children's Hospital of Chicago1
Assistance Publique - Hôpitaux de Paris1
Barbara Ann Karmanos Cancer Institute1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive36
Leukemia, Myeloid, Acute15
Precursor Cell Lymphoblastic Leukemia-Lymphoma15
Leukemia, Lymphocytic, Chronic, B-Cell12
Myelodysplastic Syndromes12
Leukemia11
Multiple Myeloma11
Hodgkin Disease10
Lymphoma, Non-Hodgkin9
Myeloproliferative Disorders7

Trials

Showing 1 to 25 of 36. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.